ADMA Biologics Reports Strong Q1 Profitability, 70.5% Gross Margin, and Initiates $125M Share Repurchase

summarizeSummary

ADMA Biologics reported strong first-quarter 2026 results with a 68.5% increase in net income, significant gross margin expansion, and a positive swing in operating cash flow, alongside the initiation of a $125 million accelerated share repurchase.

check_boxKey Events

• Strong Q1 Financial Performance

  Net income for the three months ended March 31, 2026, increased by 68.5% to $45.3 million, up from $26.9 million in the prior year period. Diluted EPS rose to $0.19 from $0.11.

• Significant Gross Margin Expansion

  Gross profit increased to $80.8 million, resulting in a gross margin of 70.5% for Q1 2026, a substantial improvement from 53.2% in Q1 2025, primarily due to favorable product mix and yield enhancement manufacturing processes.

• Positive Operating Cash Flow Turnaround

  Net cash provided by operating activities was $58.2 million in Q1 2026, a significant increase from net cash used in operating activities of $19.7 million in Q1 2025.

• ASCENIV Sales Growth

  ASCENIV sales grew by 27.7% to $97.5 million, offsetting a decrease in BIVIGAM sales due to competitive pressures.

auto_awesomeAnalysis

ADMA Biologics delivered a robust first quarter, showcasing significant financial improvements. Net income surged by 68.5% year-over-year, driven by a substantial increase in gross profit and a remarkable expansion in gross margin from 53.2% to 70.5%. The company also achieved a significant turnaround in operating cash flow, moving from a deficit to a strong positive. This strong performance was primarily fueled by a 27.7% growth in ASCENIV sales, despite competitive pressures impacting BIVIGAM sales. The company also initiated a $125 million accelerated share repurchase program, funded by its revolving credit facility, demonstrating a commitment to returning capital to shareholders. This positive financial report follows the recent FDA approval for ASCENIV's pediatric label expansion, further strengthening the product's market potential.